FibroBiologics (NASDAQ:FBLG – Get Free Report) released its earnings results on Monday. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.25, FiscalAI reports.
FibroBiologics Price Performance
Shares of NASDAQ FBLG traded down $0.02 during trading hours on Monday, hitting $0.90. 97,460 shares of the company’s stock were exchanged, compared to its average volume of 230,361. The company’s 50-day moving average price is $1.18 and its 200-day moving average price is $2.13. FibroBiologics has a 1-year low of $0.62 and a 1-year high of $9.60. The stock has a market capitalization of $6.01 million, a price-to-earnings ratio of -0.17 and a beta of 1.81.
Analysts Set New Price Targets
FBLG has been the topic of several recent analyst reports. Deutsche Bank cut shares of FibroBiologics to an “underperform” rating in a report on Tuesday, August 4th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, September 4th. Wall Street Zen raised shares of FibroBiologics to a “hold” rating in a research report on Saturday, October 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price (down from $8.00) on shares of FibroBiologics in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, FibroBiologics currently has a consensus rating of “Reduce” and a consensus target price of $73.00.
FibroBiologics Company Profile
FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.
Read More
- Five stocks we like better than FibroBiologics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
